REGN

El interés en corto de Regeneron Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Regeneron Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Regeneron Pharmaceuticals (NASDAQ:REGN) Bolsa, Informe de interés en corto

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

REGENERON PHARMACEUTICALS ORD

Regnum Corp

In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) against its key competitors in the Biotechnology industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Regeneron Pharmaceuticals Background</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>20.52</td>
<td>3.11</td>
<td>6.90</td>
<td>4.66%</td>
<td>$1.63</td>
<td>$3.23</td>
<td>10.65%</td>
</tr>
<tr>
<td>AbbVie Inc</td>
<td>70.27</td>
<td>59.08</td>
<td>6.44</td>
<td>24.22%</td>
<td>$4.88</td>
<td>$10.25</td>
<td>3.83%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>40.78</td>
<td>22.80</td>
<td>5.30</td>
<td>42.08%</td>
<td>$5.27</td>
<td>$5.19</td>
<td>23.18%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>110.02</td>
<td>6.14</td>
<td>4.06</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>16</td>
<td>1.58</td>
<td>2.69</td>
<td>2.41%</td>
<td>$0.69</td>
<td>$1.83</td>
<td>-2.55%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>16.82</td>
<td>2.80</td>
<td>6.79</td>
<td>5.24%</td>
<td>$0.42</td>
<td>$0.67</td>
<td>22.89%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>858.67</td>
<td>4.69</td>
<td>4.08</td>
<td>3.45%</td>
<td>$0.18</td>
<td>$1.05</td>
<td>23.81%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>18.48</td>
<td>3.20</td>
<td>5.39</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>39.78</td>
<td>2.32</td>
<td>4.63</td>
<td>1.98%</td>
<td>$0.16</td>
<td>$0.56</td>
<td>28.28%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>32.41</td>
<td>4.53</td>
<td>5.61</td>
<td>4.97%</td>
<td>$0.19</td>
<td>$0.61</td>
<td>24.72%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>166.68</td>
<td>11.07</td>
<td>8.12</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Exelixis Inc</td>
<td>22.43</td>
<td>4.36</td>
<td>5.03</td>
<td>5.37%</td>
<td>$0.2</td>
<td>$0.52</td>
<td>14.33%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>2.03</td>
<td>1.59</td>
<td>61.62</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Average</td>
<td>116.2</td>
<td>10.35</td>
<td>9.98</td>
<td>8.79%</td>
<td>$1.44</td>
<td>$2.64</td>
<td>30.61%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By thoroughly analyzing Regeneron Pharmaceuticals, we can discern the following trends: 
<ul>
<li>
The stock's Price to Earnings ratio of 20.52 is lower than the industry average by 0.18x, suggesting potential value in the eyes of market participants.
</li>
<li>
Considering a Price to Book ratio of 3.11, which is well below the industry average by 0.3x, the stock may be undervalued based on its book value compared to its peers.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 6.9, which is 0.69x the industry average.
</li>
<li>
The company has a lower Return on Equity (ROE) of 4.66%, which is 4.13% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
The company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.63 Billion, which is 1.13x above the industry average, indicating stronger profitability and robust cash flow generation.
</li>
<li>
With higher gross profit of $3.23 Billion, which indicates 1.22x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 10.65% compared to the industry average of 30.61%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730905231_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is a measure that indicates the level of debt a company has taken on relative to the value of its assets net of liabilities.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing Regeneron Pharmaceuticals against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
Regeneron Pharmaceuticals demonstrates a stronger financial position compared to its top 4 peers in the sector.
</li>
<li>
With a lower debt-to-equity ratio of 0.09, the company relies less on debt financing and maintains a healthier balance between debt and equity, which can be viewed positively by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Regeneron Pharmaceuticals in the Biotechnology industry, the PE, PB, and PS ratios are all low compared to peers, indicating potential undervaluation. However, the low ROE suggests lower profitability efficiency. On the positive side, the high EBITDA and gross profit levels indicate strong operational performance. The low revenue growth may be a concern for future prospects compared to industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Markets

Trading Ideas

Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry

Oppenheimer analyst Hartaj Singh maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1150 to $1000.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1000

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year
Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial

Health Care

General

Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11

Just two weeks ago, Upstream Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of <a href="https://www.benzinga.com/pressreleases/24/10/g41344387/upstream-bio-announces-closing-of-293-million-upsized-initial-public-offering-including-full-exerc" target="_blank" rel="noreferrer noopener">approximately $293 million</a>.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders.
<ul>
<li>Piper Sandler initiated coverage on Upstream Bio with an Overweight rating and a <a href="https://www.benzinga.com/quote/UPB/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $75</a>.</li>
<li>William Blair has also initiated coverage of Upstream Bio with an Outperform rating </li>
</ul>
Piper Sandler noted the company&#8217;s lead program, verekitug, has a differentiated mechanism of action that targets the TSLP receptor vs. ligand.
The TSLP ligand has been de-risked by AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) / Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Tezspire&#8217;s 2021 approval in severe asthma, the analyst says. It represents a rapidly growing biologic market opportunity of over $7.5 billion.
Piper analyst writes, &#8220;verekitug&#8217;s key advantage is its durability given its high potency, enabling Q12W dosing and potentially up to Q24W dosing, which is significantly lower compared to other biologics such as Tezspire (Q4W dosing) and Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) / Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (Q2W dosing).
William Blair also based its rating on the blockbuster potential of verekitug in large indications, including asthma and chronic obstructive pulmonary disease (COPD).
&#8220;The analyst writes that &#8220;Verekitug has the potential to deliver differentiated efficacy and longer dosing intervals than currently approved biologics for the treatment of asthma, most notably the TSLP antibody Tezspire, which targets the ligand.
William Blair writes that demonstrating clinical efficacy at least comparable to Tezspire, with dosing intervals of every three to six months, could position the therapy as a blockbuster, aligning with patient preferences for fewer doses.
However, early preclinical and clinical data for verekitug indicate a potential for even greater efficacy than Tezspire, which could exceed current baseline expectations.
Price Action: Upstream Bio stock is up 12.5% at $28.30 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41753290/ferrari-slows-down-q3-shipment-drop-hits-the-brakes-on-stock-growth" target="_blank" rel="noreferrer noopener">Ferrari Slows Down, Q3 Shipment Drop Hits the Brakes On Stock Growth</a></li>
</ul>

Analyst Color

Biotech

Initiation

Movers

AMGN

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Regeneron Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 60%, bearish.
Out of all of the special options we uncovered, 16 are puts, for a total amount of $5,066,701, and 4 are calls, for a total amount of $205,030.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $420.0 to $1120.0 for Regeneron Pharmaceuticals over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Regeneron Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Regeneron Pharmaceuticals's substantial trades, within a strike price spectrum from $420.0 to $1120.0 over the preceding 30 days.
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730750439_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$233.0</td>
<td>$224.0</td>
<td>$232.48</td>
<td>$1060.00</td>
<td>$2.0M</td>
<td style="text-align: right;">95</td>
<td style="text-align: right;">91</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.0</td>
<td>$203.9</td>
<td>$209.06</td>
<td>$1040.00</td>
<td>$837.4K</td>
<td style="text-align: right;">98</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$99.0</td>
<td>$90.8</td>
<td>$97.52</td>
<td>$930.00</td>
<td>$485.0K</td>
<td style="text-align: right;">99</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$190.0</td>
<td>$181.4</td>
<td>$189.9</td>
<td>$1020.00</td>
<td>$379.9K</td>
<td style="text-align: right;">126</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$69.7</td>
<td>$64.0</td>
<td>$67.8</td>
<td>$880.00</td>
<td>$271.2K</td>
<td style="text-align: right;">49</td>
<td style="text-align: right;">40</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Regeneron Pharmaceuticals's Current Market Status</h3>
<ul>
<li>Trading volume stands at 391,366, with REGN's price down by -1.56%, positioned at $830.46.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 88 days.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $1138.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Regeneron Pharmaceuticals, targeting a price of $1150. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1080. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $1215. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1065. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Regeneron Pharmaceuticals, targeting a price of $1184. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On Regeneron Pharmaceuticals

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1235 to $1184.

Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1184

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1260 to $1215.

RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1215

Barclays analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1080 to $1065.

Barclays Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1065

BMO Capital analyst Evan David Seigerman maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1300 to $1190.

BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1190

Truist Securities analyst Srikripa Devarakonda maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1137 to $1126.

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $1126

Piper Sandler analyst Christopher Raymond maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1242 to $1195.

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195

On Thursday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.69</a>.
The company reported sales of $3.72 billion, up 11%, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41647880/regeneron-reports-third-quarter-2024-financial-and-operating-results" rel="noreferrer noopener">consensus of $3.67 billion</a>.
&#8220;Regeneron&nbsp;had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent,&#8221; said&nbsp;Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of&nbsp;Regeneron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41208078/regeneron-chief-flags-health-risks-with-popular-weight-loss-medications-like-ozempic-says-company" rel="noreferrer noopener">Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs</a>
&#8220;Our strong third quarter financial performance was highlighted by double-digit revenue growth and continued investment in our growing pipeline,&#8221; said Christopher Fenimore, Senior Vice President, Finance and Chief Financial Officer of Regeneron.
Third quarter 2024 U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;increased 3% versus third quarter 2023 to $1.54&nbsp;billion, including $392 million from Eylea HD.
A lower net selling price adversely impacted the net product sales of EYLEA in the third quarter of 2024.
Libtayo&nbsp;global net sales increased by 25% to $289 million.
Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) collaboration revenue increased from $1.06 billion to $1.26 billion.
The company said its obesity clinical program is now enrolling.
In its earnings <a target="_blank" href="https://investor.regeneron.com/static-files/4ac68b22-7abe-4d1f-a15a-2a9b739cc935" rel="noreferrer noopener">presentation</a>, Regeneron said Phase 2 study to investigate if addition of trevogrumab (anti-myostatin) to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide with and without garetosmab (antiactivin A) improves the quality of weight loss and/or improves maintenance of weight loss post semaglutide discontinuation.
Safety and tolerability data for high-dose trevogrumab in healthy volunteers showed no new safety signals.
The company is on track to complete enrollment by year-end 2024; results for both primary endpoints are expected in 2H25.
Price Action: REGN stock is down 10.7% at $824.28 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41656437/cignas-q3-profit-beats-street-on-strong-demand-for-pharmacy-benefit-managements-specialty-drugs-new" target="_blank" rel="noreferrer noopener">Cigna&#8217;s Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management&#8217;s Specialty Drugs, New Clients</a></li>
</ul>

Earnings

Large Cap

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices <a href="https://www.benzinga.com/markets">in nearly two months.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) plummeted over 5% by midday trading in New York, on track for its worst session in two years. Although the company surpassed earnings estimates, it forecasted slower growth in its Azure cloud business, dampening future revenue expectations.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) also declined by over 4% despite a strong quarterly performance, as the social media giant projected &#8220;significant&#8221; capital expenditure growth next year, particularly for AI infrastructure.
The elite &#8220;Magnificent Seven&#8221; tech group shed nearly $500 billion in market capitalization within a single day after reaching a record high of $16.8 trillion. Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are set to report earnings after the market close.
In economic news, inflation sent mixed signals for September. The Personal Consumption Expenditures (PCE) price index slowed as expected to 2.1% annually, while the Fed's preferred inflation measure, the core PCE price index, remained at 2.7% year over year, slightly <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41658542/fed-interest-rate-cuts-expected-but-economists-warn-of-bumpy-course-in-this-last-">above the expected 2.6%.</a>
The S&amp;P 500 dropped 1.4%, and the tech-heavy Nasdaq 100 slid 2.2%, both tracking their worst session since Sept. 6. The CBOE Volatility Index (VIX) surged 12%.
Risk aversion also weighed on commodities, with gold prices dropping 1.7%, marking their worst day since July, and silver plunging 3% after a 2% decline on Wednesday. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) slid 2.4%, and crypto-related stocks suffered significant losses. Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) tumbled over 10% on disappointing earnings, eyeing its worst day since May.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,832.30</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,729.43</td>
<td>-1.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,943.07</td>
<td>-2.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 1.5% to $571.51.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.8% to $418.60.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) tumbled 2.2% to $485.78. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $219.65.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1.4%. The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 2.4%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to corporate earnings were: 
<ul>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), up over 5%, </li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), up 1.7%,</li>
<li>Starbucks Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>), down 0.6%, </li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>), down over 8%, </li>
<li>MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), up 1.9%,</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), up 24%,</li>
<li>Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), down 1.8%, </li>
<li>Merck &amp; Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), down 2.8%,</li>
<li>Linde plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>), down 2.9%, </li>
<li>Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), up 2.9%, </li>
<li>Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), down over 11%, </li>
<li>Eaton Corp. plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>), down 5%, </li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), up 6%, </li>
<li>Bristo-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), up 3.3%, </li>
<li>Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>), up 2.2%, </li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>), up 7.6%, </li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), down 9%, </li>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), up 3%, </li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>), up over 9%. </li>
<li>Cheniere Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>), up over 5%. </li>
</ul>
Large-cap companies slated to report their earnings after the close include Apple Inc, Amazon.com Inc, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) and Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41658754/microsoft-in-major-growth-mode-not-slowing-down-4-analysts-see-strong-azure-demand-">Microsoft &#8216;In Major Growth Mode,&#8217; Not Slowing Down: 4 Analysts See Strong Azure Demand, AI Monetization Efforts</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

AAPL

AMZN

BKNG

CMCSA

COIN

CTRA

CVNA

SPDR Dow Jones Industrial Average ETF Trust

EBAY

INTC

MSFT

MSTR

NCLH

SBUX

TEAM

UBER

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?

WIIM

Regeneron shares are trading lower following Q3 earnings.

Guidance

Regeneron Sees FY24 Non-GAAP Gross Margin On Net Product Sales Approximately 89%, Unchanged From Prior

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported quarterly earnings of $12.46 per share which beat the analyst consensus estimate of $11.69 by 6.59 percent. The company reported quarterly sales of $3.720 billion which beat the analyst consensus estimate of $3.670 billion by 1.36 percent. This is a 10.62 percent increase over sales of $3.363 billion the same period last year.

Earnings Beats

Regeneron Pharmaceuticals Q3 2024 Adj. EPS $12.46 Beats $11.69 Estimate, Sales $3.720B Beat $3.670B Estimate

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">consensus of $12.76 billion</a>.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Pelabresib filing was further delayed, triggering a $800 million impairment charge related to the $2.9 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38497134/morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer" rel="noreferrer noopener">acquisition of MorphoSys</a>.
Earlier this year, MorphoSys faced&nbsp;a burgeoning safety concern surrounding&nbsp;pelabresib.
Goldman Sachs notes that MorphoSys-related impairment charge is somewhat underwhelming, raising doubts about the company&#8217;s M&amp;A strategy.
Truist notes that Novartis is concentrating on preparing the market for the PSMAFore label, which is expected to triple its addressable market.
They also pointed out that growth opportunities in China and Japan, and metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease, could push Pluvicto&#8217;s sales well above the projected $2 billion peak.
The company is committed to maximizing the potential of Pluvicto and its radioligand therapy (RLT) portfolio.
For other radiopharmaceutical companies targeting PSMA, entering this market may become more challenging.
A crucial question remains regarding the standards that must be met to compete with more effective radioligand products. This context relates to companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which have RLT products in their pipelines, as well as smaller companies, including Y-mAbs Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) and Perspective Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>).
Novartis highlighted continued strong growth and momentum and sees room to grow the market size for B-cell inhibition in multiple sclerosis, relating Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Truist highlights Novartis&#8217; strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few larger bolt-on acquisitions.
A Truist analyst indicated that they will be monitoring how the adoption of Leqvio may affect Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Repatha and Regeneron Pharmaceuticals Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Praluent. Meanwhile, Novartis has reported that the launch is advancing smoothly, and Leqvio continues to grow, outpacing the overall market as per the management.
Novartis&#8217; Cosentyx witnessed strong uptake and continued brand growth driven by hidradenitis suppurativa expansion, and the market opportunity can accommodate several players, Abbvie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>), Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>).
Price Action: NVS stock is down 0.48% at $110.00 at last check Wednesday.
Photo by Taljat David via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629995/orthopedic-implant-maker-zimmer-biomet-reports-better-than-expected-q3-earnings-updates-annual-fore" target="_blank" rel="noreferrer noopener">Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts</a></li>
</ul>

ABBV

BIIB

CATX

INCY

KYMR

YMAB

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

EyePoint Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) stock is trading higher on Monday after the company revealed interim 16-week data from the ongoing Phase 2 VERONA trial of Duravyu for patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41569697/eyepoint-pharmaceuticals-announces-positive-interim-16-week-data-for-ongoing-phase-2-verona-clinic" rel="noreferrer noopener">diabetic macular edema (DME)</a>.
Duravyu is an investigational sustained-delivery therapy that delivers patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.
Duravyu 2.7mg demonstrated an early, sustained, and clinically meaningful improvement in best-corrected visual acuity (BCVA) and anatomical control versus the Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept) control arm.
A favorable safety and tolerability profile continued for both Duravyu arms.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38641939/why-is-eyepoint-pharmaceuticals-stock-plummeting-on-monday" rel="noreferrer noopener">Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?</a>
The 2.7mg dose is also being evaluated in the Phase 3 pivotal trials for wet age-related macular degeneration&nbsp;(wet AMD).
The company expects to report the full topline results in the first quarter of 2025.
Duravyu 2.7mg demonstrated an early and sustained improvement in BCVA and CST (central subfield thickness) as measured by optical coherence tomography (OCT).
<ul>
<li>BCVA improved +8.9 letters versus +3.2 letters for aflibercept control compared to baseline.</li>
<li>CST improved 68.1 microns versus 30.5 microns for aflibercept control compared to baseline.</li>
</ul>
Visual and anatomical gains were observed at Week 4, demonstrating the immediate bioavailability of DURAVYU.
The positive trend in BCVA and anatomy continued for patients who reached the Week 24 visit.
Continued to show encouraging safety and tolerability profile with no Duravyu-related ocular or systemic serious adverse events.
At 16 weeks, 2% of eyes in the Duravyu 2.7 mg arm were supplement-free, compared to 50% in the aflibercept control arm.
Price Action: EYPT stock is up 36.7% at $12.99&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41578225/why-is-nao-cap-neurology-focused-autonomix-medical-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Nao-Cap Neurology Focused Autonomix Medical Stock Trading Higher On Monday?</a></li>
</ul>

EYPT

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

On Friday, Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), which will be presented at the Fall <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41540619/lillys-ebglyss-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-and-itch-re" rel="noreferrer noopener">Clinical Dermatology Conference</a>.
The results show that Ebglyss improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) / Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab).
The study&#8217;s primary endpoint was measured by at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) score at 16 weeks, which evaluates the extent and severity of the skin disease.
Secondary endpoints at 16 and 24 weeks included Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline and at least a four-point improvement in Pruritus NRS from baseline.
With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with dupilumab achieved EASI-75.
In addition, 46% of patients who were inadequate responders to dupilumab achieved EASI-75 response with Ebglyss at Week 16.
53% and 62% of ADapt patients who discontinued dupilumab and began treatment with Ebglyss also experienced itch relief (Pruritus NRS) with at least a four-point improvement from baseline at Week 16 and Week 24, respectively.
Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss.
52% treated with Ebglyss saw clear or almost clear face dermatitis at Week 24.
Among patients with moderate-to-severe hand dermatitis at baseline, the modified total lesion-symptom score, which measures the extent and severity of hand dermatitis, decreased by 75 percent at Week 24.
Less than 6% of patients treated with Ebglyss experienced an adverse event that led to treatment discontinuation.
Last month, the FDA approved Ebglyss, a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss" rel="noreferrer noopener">topical prescription therapies</a>.
Ebglyss was also approved in the European Union in 2023 and Japan in January 2024, with additional markets expected later this year.
Price Action: LLY stock is up 0.32% at $894.15 at last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41551304/bkvs-integrated-operations-offer-value-analyst-highlights-unique-closed-loop-system" target="_blank" rel="noreferrer noopener">BKV&#8217;s Integrated Operations Offer Value, Analyst Highlights Unique &#8216;Closed-Loop&#8217; System And Growth Prospects</a></li>
</ul>

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and maintains $1260 price target.

Reiteration

RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1260 Price Target

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more... With the rapidly increasing drug discovery and sequential approvals, surging R&amp;D initiatives, coupled with recent Fed rate cuts likely to encourage funding and investing, the biotech industry is positioned to experience solid growth. Also, advancements in technologies are swiftly accelerating the prospects of the market.
Given the industry's positive prospects, it could be ideal to invest in fundamentally strong biotech stocks Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) with promising pipelines.
The role of the biotech industry in today's generation is continuously expanding with increasing incidents of chronic diseases and conditions, rising demand for personalized medicine, and rapid acceleration in drug discovery fueled by the application of cutting-edge technologies like Artificial Intelligence (AI).
Over 38 new drugs have been approved by the <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">U.S. Food and Drug Administration (FDA)</a> this year to address conditions such as schizophrenia, urinary tract infections, breast cancer, and lung cancer and to treat Alzheimer's disease. The increased drug discovery and intense research and development (R&amp;D) will potentially accelerate further breakthroughs.
Also, the biotech industry is poised to capitalize on the <a href="https://www.biopharmadive.com/news/biotech-interest-rates-impact-startups-venture-capital/727479/#:~:text=During%20the%20Fed's%20recent%20tightening,for%20those%20companies%20already%20public.">Federal Reserve's recent interest rate cut</a>. The rate cut resulted in lower borrowing costs. It could potentially lead to increased investment and improve the market sentiment.
Moreover, the global biotechnology market is expected to reach $4.61 trillion by 2034, growing at a <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion%20in%202024%20and%20is%20expected%20to%20reach%20around%20USD%204.61%20trillion%20by%202034%2C%20expanding%20at%20a%20CAGR%20of%2011.5%25%20from%202024%20to%202034.">CAGR of 11.5%</a>. The U.S. biotechnology market is predicted to be worth around $830.31 billion by 2034. Strong R&amp;D initiatives, increasing drug approvals, and improvement of healthcare infrastructure are driving the market growth.
Further, the increasing application of generative AI in Biotech to design novel molecules, proteins, and drugs is revolutionizing the drug discovery and development processes. With this accelerating innovation and drug candidate identification, the <a href="https://www.pharmiweb.com/press-release/2024-04-15/generative-ai-in-biotech-market-to-skyrocket-to-usd-472-million-by-2032-marketresearchbiz#:~:text=Generative%20AI%20in%20Biotech%20utilizes,innovation%20and%20drug%20candidate%20identification.">generative AI in the biotech market</a> is expected to grow to $472 million by 2032 at a CAGR of 24.9%.
Considering the encouraging economic trends, let's delve into the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics globally. The company's principal products include Enbrel, Otezla, Prolia, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, and KRYSTEXXA.
On August 20, AMGN announced the availability of Otezla&#xAE; (apremilast) in the U.S. for pediatric use. The U.S. FDA approved Otezla earlier this year for treating moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy.
This is currently the first and only FDA-approved oral medication for children and adolescents ages 6-17 with moderate to severe plaque psoriasis.
On June 14, AMGN announced that the FDA approved BLINCYTO to treat adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase.
BLINCYTO is the first and only globally approved Bispecific T-cell Engager (BiTE&#xAE;) immuno-oncology therapy that targets CD19 surface antigens on B cells. It demonstrated superior overall survival versus chemotherapy alone.
During the third quarter that ended September 30, 2024, AMGN reported total revenues of $8.50 billion, up 23.2% year-over-over. Its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew 18.8% from the year-ago value to $4.04 billion. The company's non-GAAP net income and EPS amounted to $3.02 billion and $5.58, indicating increases of 13.4% and 12.5% from the prior year's quarter, respectively.
Furthermore, the company's free cash flow rose 32% from the prior year period to $3.30 billion.
For the full year 2024, AMGN expects total revenues in the range of $33 billion to $33.80 billion and non-GAAP EPS in the range of $19.20 to $20.00.
Analysts expect AMGN's revenue and EPS for the fourth quarter (ending December 2024) to grow 8.2% and 8.3% year-over-year to $8.87 billion and $5.10, respectively. Also, the company topped the consensus EPS and revenue estimates in three of the four trailing quarters.
Shares of AMGN have surged 16.9% over the past six months and 25.2% over the past year to close the last trading session at $320.16.
AMGN's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
AMGN has a B grade for Quality. It is ranked #25 out of 329 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have AMGN ratings for Value, Momentum, Stability, Growth, and Sentiment. Get all AMGN ratings <a href="https://stocknews.com/stock/AMGN/">here</a>.
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
On October 18, REGN announced positive three-year data for EYLEA HD&#xAE; (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema (DME). Patients who switched to EYLEA HD experienced substantially slower fluid reaccumulation.
The phase 3 PHOTON trial continued to demonstrate that EYLEA HD can safely provide meaningful and lasting vision and anatomical benefits for people living with diabetic macular edema and can prove to be revolutionary for the patients.
On September 27, REGN and Sanofi received FDA approval for Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. This marked Dupixent as the first biological medicine approved in the U.S. to treat these patients.
During the third quarter that ended September 30, 2024, REGN's revenues increased 10.6% year-over-year to $3.72 billion. Its income from operations increased 6.2% from the year-ago value to $1.18 billion. The company's non-GAAP net income came in at $1.46 billion or $12.46 per share, indicating growth of 10% and 7.5% year-over-year, respectively.
Street expects REGN's revenue for the first quarter (ending March 2025) to increase 16.4% year-over-year to $3.66 billion, while its EPS is expected to grow 19.7% year-over-year to $11.43, respectively. Furthermore, the company surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
REGN's stock has gained 7.5% over the past year to close the last trading session at $838.20.
REGN's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
The stock has a B grade for Value and Quality. REGN is ranked #9 among 329 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/REGN/">Click here</a> to access REGN's ratings for Momentum, Growth, Stability, and Sentiment.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs internationally. The company provides products like Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla.
On October 31, GILD and AbTherx, a biotechnology company with innovative technologies, expanded their previous agreement to develop novel antibody discovery technologies and discover therapeutic antibodies for Gilead-selected targets. The expanded partnership will include additional technologies and multiple new research programs.
On October 02, GILD entered into a non-exclusive, royalty-free voluntary licensing agreement with Hetero, India's leading pharmaceutical company, to manufacture and distribute lenacapavir in 120 countries. The strategic agreement is in line with GILD's vision and will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretroviral.
The partnership will aid the efforts to prevent HIV through pre-exposure prophylaxis (PrEP).
During the second quarter that ended June 30, 2024, GILD's total revenues were up 5.4% year-over-year to $6.95 billion, and its operating income grew 58.8% from the prior year quarter to $2.64 billion. Also, the company's non-GAAP net income and EPS totaled $2.52 billion and $2.01, up 49.2% and 50% from the prior year's quarter, respectively.
As per the company's full-year guidance, GILD projects product sales to range between $27.10 billion and $27.50 billion. It also expects non-GAAP EPS to be between $3.60 and $3.90, an increase from the previous $3.45 to $3.85 guidance.
Street expects GILD's revenue for the fiscal year (ending December 2025) to increase 1.1% year-over-year to $28.05 billion, and its EPS for the same period is expected to grow 91.9% year-over-year to $7.26. Also, the company surpassed the consensus revenue estimates in all trailing four quarters, which is impressive.
GILD's stock has gained 36.2% over the past six months and 13.1% over the past year to close the last trading session at $88.82.
GILD's POWR Ratings reflect its robust outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
The stock has an A grade for Value. It also has a B grade for Sentiment and Quality. Within the same industry, GILD is ranked #3 among 329 stocks.
<a href="https://stocknews.com/stock/GILD/">Click here</a> to access additional ratings of GILD for Momentum, Growth, and Stability.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
AMGN shares were unchanged in after-hours trading Friday. Year-to-date, AMGN has gained 13.28%, versus a 21.27% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/amgn-gild-regn-3-biotechnology-stocks-with-promising-pipelines/>3 Biotechnology Stocks With Promising Pipelines</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotechnology Stocks With Promising Pipelines

S&P 500 Ends 5-Month Rally With October Downturn

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,...

TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)

A bit of earnings and election jitters roiled the market last week reordering  the leaderboard in biopharma stocks.

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report), Travere Therap...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Regeneron (REGN ...

Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or EoE, i...

Regeneron, Sanofi announce EC approval for Dupixent

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, investors might consider adding fundamentally strong biotech stocks like Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD) to their portfolio for an impactful investment. Continue reading… As the medical breakthroughs progress, biotech stocks are expected to play a significant role in revolutionizing healthcare. Medical advancements in neuroscience and gene therapy have opened up new horizons within this sector.
Therefore, investors looking to benefit from such contribution to the economy might consider biotech stocks, namely, Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>).
Innovations targeting neurological disorders, such as Alzheimer's and Parkinson's, promise to transform treatment approaches by developing therapies that address the underlying causes of these conditions. Several collaborations <a href="https://www.nature.com/articles/d43747-024-00091-x">involving large pharma companies signal a renewed interest in the neuroscience sector</a>. Moreover, the companies are already moving on to early successes in neurotherapeutics, bringing hope to millions of patients.
The expanding field of gene-editing technology is also attracting significant investment interest as companies develop cancer therapies and other targeted treatments. There have been <a href="https://www.pharmaceutical-technology.com/data-insights/cell-gene-therapy-in-pharma/?cf-view">cell and gene therapy advancements </a>like a recombinant AAV vector for glioblastoma treatment, peptide-modified AAV capsids for muscle targeting, and oral delivery systems for oligonucleotides.
So far this year, the FDA has approved <a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products">38 cellular and gene therapy products</a> and also <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">38 novel drugs</a> that target conditions from lung cancer to Alzheimer's disease and various other chronic ailments. Furthermore, the global biotechnology market is anticipated to reach $4.61 trillion by 2034, <a href="https://www.precedenceresearch.com/biotechnology-market">growing at a CAGR of 11.5%</a>.
The biotech industry offers an avenue that aligns financial and societal goals, paving the way for transformative impacts in medicine.
With that in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, starting with the third choice.
Stock #3: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.  The company's products include EYLEA injection, Dupixent Injection, Libtayo Injection, Praluent Injection, Kevzara Injection, and others.
On November 6, REGN received approval from the European Commission for Dupixent&#xAE; (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1 to 11 years. This approval expands EoE in adults and adolescents, creating a milestone in treating pediatric patients.
On October 18, REGN announced positive data for EYLEA HD&#xAE; (aflibercept) injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema (DME). It demonstrates continued durable vision and anatomic improvements among 88% of EYLEA HD patients in this phase. 
REGN, for the third quarter (ended September 30, 2024), reported total <a href="https://www.investopedia.com/terms/r/revenue.asp">revenues</a> of $3.72 billion, indicating a 10.6% growth from the prior year quarter. Its income from operations increased 6.2% year-over-year to $1.18 billion. The company's non-GAAP net income came in at $1.46 billion and $12.46 per share, up 10% and 7.5% year-over-year, respectively.
The consensus revenue estimate of $3.63 billion for the fiscal first quarter (ending March 2025) represents a 15.4% increase year-over-year. The consensus EPS estimate of $10.99 for the same quarter indicates a 15.1% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
The stock has surged marginally over the past year to close the last trading session at $829.43.
REGN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
REGN has a B grade for Value and Quality. It is ranked #25 out of 328 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/REGN/">Click here</a> to see the additional ratings for REGN (Growth, Momentum, Stability, and Sentiment).
Stock #2: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). 
On October 29, BIIB and Neomorph Inc. collaborated on research to discover and develop molecular glue degraders for Alzheimer's, rare neurological and immunological diseases. This collaboration is under the terms where Neomorph's molecular glue degrader platform and BIIB's expertise with cutting-edge innovation will be able to create a meaningful therapy for the patients.  
In the same month, BIIB received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for felzartamab, an investigational anti-CD38 monoclonal antibody. It is used to treat late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant patients. This designation will enhance the efficiency in the development of the antibody.
For the third quarter of 2024, which ended on September 30, BIIB's total revenues stood at $1.77 billion. The company's net income stood at $388.50 million compared to the prior-year quarter's loss of $68.10 million, while its EPS came in at $2.66 versus a loss of $0.47 per share last year. In addition, BIIB's adjusted free cash flow rose 73.8% from the year-ago value to $900.60 million.
Per the updated financial guidance for the full year 2024, BIIB now forecasts non-GAAP EPS between $16.10 and $16.60, up from the previous estimate of $15.75 and $16.25.
Street expects BIIB's revenue for the fiscal fourth quarter (ending December 2024) to increase 1.2% year-over-year to $2.41 billion. Its EPS for the same period is expected to register a 16.8% growth from the prior year, settling at $3.44. In addition, it surpassed the EPS estimates in three of the trailing four quarters, which is promising.
BIIB's stock has surged 1.9% intraday to close the last trading session at $176.93.
BIIB's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and a B for Growth and Sentiment. Within the same industry, it is ranked #7 out of 328 stocks. <a href="https://stocknews.com/stock/BIIB/">Click here</a> to see BIIB's ratings for Momentum, Stability, and Quality.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company dedicated to advancing treatments for life-threatening diseases such as human immunodeficiency virus (HIV), viral hepatitis, COVID-19, and cancer.  Its portfolio of marketed products includes Biktarvy, Genvoya, Odefsey, Truvada, Harvoni, Vemlidy, and Veklury, among others.
On October 2, GILD signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and sell generic lenacapavir (pending regulatory approval) in 120 countries (mainly low- and lower-middle-income) with high HIV incidence. This agreement is to make HIV prevention medicine available worldwide once it is approved.
On September 10, GILD and Genesis Therapeutics, Inc. announced a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
This collaboration will utilize Genesis' advanced AI platform, GEMS, to design and optimize molecules for targets chosen by GILD. The two companies will collaborate on early-stage research, with GILD holding exclusive rights to further develop and market any compounds that come from their joint efforts.
In the fiscal second quarter, which ended on June 30, 2024, GILD's total revenues increased 5.4% year-over-year to $6.95 billion. The company reported operating income of $2.64 billion, indicating 58.8% growth from the prior-year quarter. GILD's non-GAAP net income attributable came in at $2.52 billion, up 49.2% year-over-year, while its non-GAAP EPS grew 50% from the year-ago value to $2.01.
According to the full-year guidance, GILD forecasts product sales to range from $27.10 billion to $27.50 billion. The company also expects non-GAAP EPS to be between $3.60 and $3.90, an increase from the previous guidance of $6.85 to $7.25.
Analysts expect GILD's revenue and EPS for the current year (ending December 2024) to be $27.73 billion and $3.79, respectively. For the fiscal year 2025, both its revenue and EPS are expected to grow by marginally and 91.5% from the prior year to $28.05 billion and $7.26, respectively.
Over the past six months, the stock has gained 39.3%, closing the last trading session at $90.22.
GILD's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
It has an A grade for Value and a B for Sentiment and Quality. The stock is ranked #4 in the Biotech industry. <a href="https://stocknews.com/stock/GILD/">Click here</a> to access the additional GILD ratings (Growth, Momentum, and Stability).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
GILD shares were trading at $91.26 per share on Wednesday afternoon, up $1.04 (+1.15%). Year-to-date, GILD has gained 16.28%, versus a 25.37% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/gild-regn-biib-3-biotech-stocks-predicted-to-surge-on-medical-innovation/>3 Biotech Stocks Predicted to Surge on Medical Innovation</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Predicted to Surge on Medical Innovation

ALNY

ARGX

BAPR

BAUG

BJUL

BJUN

BMAR

BMAY

BOCT

BUFF

CATH

CSTNL

EFIV

GILD

HIBL

HIBS

INSM

IONS

MDGL

NOBL

NTLA

NVDA

PAPR

PAUG

PJAN

PJUN

PUTW

QDIV

QRVO

QVML

RSPT

SNPE

SNYNF

SPDN

SPDV

SPGP

SPHB

SPHD

SPHQ

SPLG

SPLV

SPMO

SPMV

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SSPY

TVTX

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

VOOG

VOOV

VRTX

XRLV

XYLD

XYLG

Screenshot 2024-09-10 at 8.49.39 PM

MAIA

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Press Releases

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

Regeneron Reports Third Quarter 2024 Financial and Operating Results

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Comments

Regeneron Pharmaceuticals

Interés en corto

Regeneron Pharmaceuticals (NASDAQ:REGN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL